Patents Assigned to RogCon, Inc.
  • Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies
    Patent number: 11939582
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of sodium voltage-gated channel alpha subunit 2 (SCN2A) in a subject. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a sodium voltage gated channel alpha subunit 1 (SCN1A) related disease or disorder (e.g., Dravet syndrome) in a subject in need.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: March 26, 2024
    Assignee: RogCon, Inc.
    Inventor: Steven Petrou